# EDGAR Filing Document

**Accession Number:** 0001077183
**File Stem:** 0001628280-25-054270
**Filing Date:** 2025-11
**Character Count:** 11226
**Document Hash:** ceb7845e77755cddd75236929c5fc938
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-25-054270.hdr.sgml**: 20251128

**ACCESSION NUMBER**: 0001628280-25-054270

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251125

**FILED AS OF DATE**: 20251128

**DATE AS OF CHANGE**: 20251128

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Olivo Alicia C
- **CENTRAL INDEX KEY:** 0001951869

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35756
- **FILM NUMBER:** 251536009

**MAIL ADDRESS:**
- **STREET 1:** 9490 NEOGENOMICS WAY
- **CITY:** FORT MYERS
- **STATE:** FL
- **ZIP:** 33912
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NEOGENOMICS INC
- **CENTRAL INDEX KEY:** 0001077183
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-TESTING LABORATORIES [8734]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 742897368
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 9490 NEOGENOMICS WAY
- **CITY:** FORT MYERS
- **STATE:** FL
- **ZIP:** 33912
- **BUSINESS PHONE:** 2397680600

**MAIL ADDRESS:**
- **STREET 1:** 9490 NEOGENOMICS WAY
- **CITY:** FORT MYERS
- **STATE:** FL
- **ZIP:** 33912

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMERICAN COMMUNICATIONS ENTERPRISES INC
- **DATE OF NAME CHANGE:** 19990120

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Olivo Alicia C<br><sub>(Last) (First) (Middle)</sub><br>9490 NEOGENOMICS WAY<br><sub>(Street)</sub><br>FORT MYERS, FL 33912<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-11-25 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_EVP, GC & Business Development_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>NEOGENOMICS INC [ NEO ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-11-25 |  | M |  | 8977 | A | $10.05 | 51999 | D |  |
| Common Stock | 2025-11-25 |  | S<sup>(1)</sup> |  | 20916 | D | $12 | 31083 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | $10.05 | 2025-11-25 |  | M |  |  | 8977 | <sup>(2)</sup> | 2029-09-01 | Common Stock | 8977 | $0 | 46355 | D |  |
| Stock Option (Right to Buy) | $19.12 |  |  |  |  |  |  | <sup>(3)</sup> | 2026-09-30 | Common Stock | 1046 |  | 1046 | D |  |
| Stock Option (Right to Buy) | $27.34 |  |  |  |  |  |  | <sup>(4)</sup> | 2027-05-01 | Common Stock | 1024 |  | 1024 | D |  |
| Stock Option (Right to Buy) | $48.99 |  |  |  |  |  |  | <sup>(5)</sup> | 2028-05-01 | Common Stock | 516 |  | 516 | D |  |
| Stock Option (Right to Buy) | $46.10 |  |  |  |  |  |  | <sup>(6)</sup> | 2028-08-01 | Common Stock | 1117 |  | 1117 | D |  |
| Stock Option (Right to Buy) | $9.45 |  |  |  |  |  |  | <sup>(7)</sup> | 2029-05-01 | Common Stock | 22222 |  | 22222 | D |  |
| Stock Option (Right to Buy) | $19.65 |  |  |  |  |  |  | <sup>(8)</sup> | 2030-05-11 | Common Stock | 36508 |  | 36508 | D |  |
| Restricted Stock Unit | $0 |  |  |  |  |  |  | <sup>(9)</sup> | <sup>(10)</sup> | Common Stock | 6503 |  | 6503 | D |  |
| Performance Stock Unit | $0 |  |  |  |  |  |  | 2026-05-11<sup>(11)</sup> | <sup>(10)</sup> | Common Stock | 19508 |  | 19508 | D |  |
| Stock Option  (Right to Buy) | $16.45 |  |  |  |  |  |  | <sup>(12)</sup> | 2034-02-23 | Common Stock | 42344 |  | 42344 | D |  |
| Restricted Stock Unit | $0 |  |  |  |  |  |  | 2026-01-13 | <sup>(10)</sup> | Common Stock | 59382 |  | 59382 | D |  |
| Performance Stock Unit | $0 |  |  |  |  |  |  | 2027-02-23<sup>(13)</sup> | <sup>(10)</sup> | Common Stock | 25330 |  | 25330 | D |  |
| Restricted Stock Unit | $0 |  |  |  |  |  |  | <sup>(14)</sup> | <sup>(10)</sup> | Common Stock | 16886 |  | 16886 | D |  |
| Stock Option  (Right to Buy) | 13.05<sup>(15)</sup> |  |  |  |  |  |  | <sup>(16)</sup> | 2035-02-21 | Common Stock | 107450 |  | 107450 | D |  |
| Restricted Stock Unit | $0 |  |  |  |  |  |  | <sup>(17)</sup> | <sup>(10)</sup> | Common Stock | 63238 |  | 63238 | D |  |

---

### Footnotes:

(1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

(2) On September 1, 2022, Ms. Olivo was granted 55,332 stock options. The options vest ratably over the first four anniversary dates of the grant date.

(3) On September 30, 2019, Ms. Olivo was granted 1,394 stock options. The options vest ratably over the first four anniversary dates of the grant date.

(4) On May 1, 2020, Ms. Olivo was granted 1,024 stock options. The options vest ratably over the first four anniversary dates of the grant date.

(5) On May 1, 2021, Ms. Olivo was granted 516 stock options. The options vest ratably over the first four anniversary dates of the grant date.

(6) On August 1, 2021, Ms. Olivo was granted 1,117 stock options. The options vest ratably over the first four anniversary dates of the grant date.

(7) On May 1, 2022, Ms. Olivo was granted 22,222 stock options. The options vest ratably over the first four anniversary dates of the grant date.

(8) On May 11, 2023, Ms. Olivo was granted 36,508 stock options. The options vest ratably over the first three anniversary dates of the grant date.

(9) On May 11, 2023, Ms. Olivo was granted 19,508 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.

(10) Once vested, the shares of common stock are not subject to expiration.

(11) On May 11, 2023, Ms. Olivo was granted 19,508 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is29,262. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at theapplicable measurement dates, subject to continued service with the Company.

(12) On February 23, 2024, Ms. Olivo was granted 42,344 stock options. The options vest ratably over the first three anniversary dates of the grant date.

(13) On February 23, 2024, Ms. Olivo was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is37,996. 50% of the number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period atthe applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of thecumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.

(14) On February 23, 2024, Ms. Olivo was granted 25,329 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.

(15) This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%.

(16) On February 21, 2025, Ms. Olivo was granted 107,450 stock options. The options vest ratably over the first three anniversary dates of the grant date.

(17) On February 21, 2025, Ms. Olivo was granted 63,238 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.

**Signature:** /s/ Alicia C. Olivo  
**Date:** 2025-11-28

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**